Training and Resources
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
KEYTRUDA® (pembrolizumab) in cervical cancer
KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a combined positive score (CPS) ≥1.
PD-L1 testing and CPS interpretation in cervical cancer
Please refer to Summary of Product Characteristics for full list of AEs and management.
More information about KEYTRUDA® (pembrolizumab) in cervical cancer
KEYTRUDA® (pembrolizumab) in endometrial cancer
KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation.
KEYTRUDA® (pembrolizumab) KEYNOTE-775 clinical data presentation
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
Detecting and managing adverse events (AEs) while evaluating potential patient benefit with KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib)
KEYTRUDA Prescribing Information (Great Britain)
KEYTRUDA Prescribing Information (Northern Ireland)
[External links]
KEYConversations: Latest advancement in systemic treatment outcomes for patients with advanced and recurrent endometrial cancer post meeting report
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
Patient assets
To order printed versions of these diaries to your place of work, please contact msdukoncology@msd.com
Please be aware you should not direct patients to this website. You should download the diary on their behalf and share it with them as appropriate.
More information about KEYTRUDA® (pembrolizumab) in endometrial cancer
KEYTRUDA® in combination with chemotherapy
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
